CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Ninlaro for Multiple Myeloma (2nd-beyond) – Details

Project Number PC0164-000
Brand Name Ninlaro
Generic Name Ixazomib
Strength 4 mg, 3 mg and 2.3 mg
Tumour Type Myeloma
Indication Multiple Myeloma (2nd-beyond)
Funding Request In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy
Review Status Complete
Pre Noc Submission No
NOC Date August 4, 2016
Manufacturer Takeda Canada Inc.
Sponsor Takeda Canada Inc.
Submission Date November 30, 2018
Submission Deemed Complete December 14, 2018
Submission Type Initial
Prioritization Requested
Stakeholder Input Deadline ‡ December 14, 2018
Check-point meeting February 7, 2019
pERC Meeting April 18, 2019
Initial Recommendation Issued May 3, 2019
Feedback Deadline ‡ May 17, 2019
pERC Reconsideration Meeting June 20, 2019
Final Recommendation Issued July 5, 2019
Notification to Implement Issued July 22, 2019
Therapeutic Area Multiple Myeloma (2nd-beyond)
Recommendation Type Do not reimburse

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.